Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV
· Real-Time Price · USD
1.06
-0.03 (-3.20%)
At close: Oct 17, 2025, 3:59 PM
1.06
0.00%
After-hours: Oct 17, 2025, 04:10 PM EDT
Enlivex Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | n/a | n/a |
Cost of Revenue | 545K | 835K | 777K | 546K |
Gross Profit | -545K | -835K | -777K | -546K |
Operating Income | -15.54M | -29.39M | -25.8M | -19.29M |
Interest Income | 1.07M | 1.56M | 835K | 120K |
Pretax Income | -15.01M | -29.07M | -31.06M | -14.47M |
Net Income | -15.01M | -29.07M | -31.06M | -14.47M |
Selling & General & Admin | 4.91M | 6.14M | 6.7M | 6.24M |
Research & Development | 10.13M | 19.23M | 18.69M | 12.88M |
Other Expenses | -48K | 4.02M | 402K | 167K |
Operating Expenses | 14.99M | 29.39M | 25.8M | 19.29M |
Interest Expense | 13K | 14K | 5.26M | 328K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 15.54M | 24.93M | 24.59M | 18.27M |
Income Tax Expense | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 20.51M | 18.57M | 18.39M | 17.86M |
Shares Outstanding (Diluted) | 20.51M | 18.57M | 18.39M | 17.86M |
EPS (Basic) | -0.73 | -1.56 | -2.31 | -0.54 |
EPS (Diluted) | -0.73 | -1.56 | -2.31 | -0.54 |
EBITDA | -14.47M | -28.22M | -25.02M | -18.74M |
EBIT | -15.01M | -29.05M | -25.8M | -19.29M |
Depreciation & Amortization | 545K | 835K | 777K | 546K |
Source: Financial Modeling Prep. Financial Sources.